CN117355523A - 血浆激肽释放酶的多环抑制剂 - Google Patents

血浆激肽释放酶的多环抑制剂 Download PDF

Info

Publication number
CN117355523A
CN117355523A CN202280033914.0A CN202280033914A CN117355523A CN 117355523 A CN117355523 A CN 117355523A CN 202280033914 A CN202280033914 A CN 202280033914A CN 117355523 A CN117355523 A CN 117355523A
Authority
CN
China
Prior art keywords
cyclopropyl
mmol
compound
independently selected
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280033914.0A
Other languages
English (en)
Chinese (zh)
Inventor
N·帕帕约安努
J·M·特拉文斯
S·J·芬克
J·M·埃拉德
A·雷
S·S·兰金
R·S·L·查普曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of CN117355523A publication Critical patent/CN117355523A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN202280033914.0A 2021-03-17 2022-03-16 血浆激肽释放酶的多环抑制剂 Pending CN117355523A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162483P 2021-03-17 2021-03-17
US63/162,483 2021-03-17
PCT/US2022/020527 WO2022197789A1 (en) 2021-03-17 2022-03-16 Polycyclic inhibitors of plasma kallikrein

Publications (1)

Publication Number Publication Date
CN117355523A true CN117355523A (zh) 2024-01-05

Family

ID=81328648

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280033914.0A Pending CN117355523A (zh) 2021-03-17 2022-03-16 血浆激肽释放酶的多环抑制剂

Country Status (5)

Country Link
US (1) US20240199613A1 (https=)
EP (1) EP4308564A1 (https=)
JP (1) JP2024510504A (https=)
CN (1) CN117355523A (https=)
WO (1) WO2022197789A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
CN114667289B (zh) 2019-09-18 2025-08-26 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
EP4031547B1 (en) 2019-09-18 2024-07-17 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof
CN118239959A (zh) * 2022-12-23 2024-06-25 上海深势唯思科技有限责任公司 环丙烷类tlr7和8抑制剂及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
NZ526472A (en) * 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
CA2569406A1 (en) * 2004-06-04 2005-12-22 Icos Corporation Methods for treating mast cell disorders
KR20080080584A (ko) * 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
WO2013052526A1 (en) * 2011-10-06 2013-04-11 Merck Sharp & Dohme Corp. Triazolyl pde10 inhibitors
JP6280546B2 (ja) * 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
CN104059069B (zh) * 2013-08-22 2016-08-10 北京康立生医药技术开发有限公司 一种替卡格雷的制备方法
WO2015164308A1 (en) * 2014-04-22 2015-10-29 Merck Sharp & Dohme Corp. FACTOR XIa INHIBITORS
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도

Also Published As

Publication number Publication date
EP4308564A1 (en) 2024-01-24
JP2024510504A (ja) 2024-03-07
US20240199613A1 (en) 2024-06-20
WO2022197789A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US11780837B2 (en) CXCR4 inhibitors and uses thereof
CN114728962B (zh) 血浆激肽释放酶抑制剂及其用途
JP7082130B2 (ja) Ｔｙｋ２阻害剤およびその使用
CA2965517C (en) Indole carboxamides compounds useful as kinase inhibitors
CN108349940B (zh) 布鲁顿酪氨酸激酶抑制剂
IL294048A (en) sos1 inhibitors
JP2022547719A (ja) Ｈｐｋ１アンタゴニストおよびその使用
CN117355523A (zh) 血浆激肽释放酶的多环抑制剂
IL311024A (en) Substituted tricyclic compounds as parp inhibitors and use thereof
CN115038688A (zh) Usp30抑制剂及其用途
TW202122382A (zh) 乙內醯脲衍生物
KR20240111312A (ko) Tyk2 분해제 및 이의 용도
CN117396474A (zh) 血浆激肽释放酶抑制剂
JP2022543515A (ja) 血漿カリクレイン阻害剤
EP4358954A1 (en) Cdk2 inhibitors and methods of using the same
CN117396469A (zh) 血浆激肽释放酶的抑制剂
TW202519211A (zh) 經取代之胺基吡啶化合物及用其治療疾病之方法
CN117396473A (zh) 血浆激肽释放酶的咪唑并吡啶基抑制剂
KR20250057699A (ko) 신규한 par-2 억제제
TWI894448B (zh) Ctla-4小分子降解劑及其應用
US20260092057A1 (en) Bcl-xl/bcl-2 degraders and uses thereof
WO2023169170A1 (zh) 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法
CN108137532A (zh) 作为人免疫缺陷病毒复制的抑制剂的吡啶-3-基乙酸衍生物
WO2024264070A2 (en) Akt inhibitors
KR20260030682A (ko) 신규한 glp-1 수용체 작용제

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination